| セッション情報 | パネルディスカッション8(肝臓学会・消化器病学会合同)東アジアにおける肝疾患の問題点と治療の特色 |
|---|---|
| タイトル | 肝PD8-2指：Characteristics of liver disease and its treatment in Korea |
| 演者 | K. H. Han（Gastroenterology Department of Internal Medicine, Yonsei University College of University, Liver Cirrhosis Clinical Research Center, Yonsei Liver Cancer Special Clinic, Severance Hospital） |
| 共同演者 | |
| 抄録 | In Korea, chronic liver disease, including chronic hepatitis and cirrhosis, was ranked the 6th most common cause of death among Koreans. Moreover, liver cancer is the 2rd most common cancer cause of death. As the early detection rate is still low despite of nationwide screening and surveillance program and the advances in diagnostic imaging techniques for the early detection of HCC, five year survival rate of HCC is still low in Korea. Therefore, prevention is a key issue to control HCC development after analyzing risk factors. About 70-75 % of HCC patients was positive for HBsAg, whereas 10-15 % of the patients was anti-HCV positive. The high incidence rate of HCC in Korea is thought to be related to the high carrier rate of hepatitis B virus (HBV) in the general population. It has been reported that 1.3% of population of more than 40 years old are infected with HCV. The HCV genotype 1 is dominant in Korea. For the primary prevention, nationwide HBV vaccination program has been conducted since late 1980’s in Korea. In the recent nation-wide survey, it was reported that HBsAg carrier rate in adults has been gradually decreased. However, despite the development and implementation of an effective vaccine, chronic hepatitis B remains a major public health problem which carries an enormous economic and social burden. After approval of reimbursement of antiviral therapy for CHB since 1998, antiviral therapy for CHB has resulted in significant reduction in patient morbidity and mortality. |
| 索引用語 | chronic hepatitis, liver cancer, cancer prevention |